Beta interferons in clinically isolated syndromes - A meta-analysis

Division of Neurology and Epidemiology, Federal University of Bahia, Salvador, BA, Brazil.
Arquivos de Neuro-Psiquiatria (Impact Factor: 0.84). 04/2008; 66(1):8-10. DOI: 10.1590/S0004-282X2008000100003
Source: PubMed


Beta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. After two years of follow-up, interferon beta decreased the risk of conversion to clinically definite MS 0.51[0.39-0.65], and delayed the time to diagnosis up to 367 days. Side-effects were mild and self limited. Our findings support the efficacy of early treatment with beta-interferon in reducing conversion to clinically defined MS in patients with clinically isolated syndromes.

15 Reads
  • Source
    • "In all of them, the episode was treated with high methylprednisolone doses, and the trials evaluated the risk of subsequent conversion to clinically definite MS, that is, the occurrence of a second acute episode, which was the primary endpoint in all studies. These studies represent evidence level 1 (recommendation grade A) and all showed that the administration of immunomodulating agents during CIS reduces the risk of a second demyelinating episode, without significant differences noted among the different types of immunomodulating agents [Clerico et al. 2008; Melo et al. 2008]. The criteria for treating CIS with disease-modifying agents are based on the identification of those patients at high risk of developing MS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management.Methods: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results.Results: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability.Conclusions: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.
    Therapeutic Advances in Neurological Disorders 11/2011; 4(6):349-60. DOI:10.1177/1756285611423560 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are currently six disease-modifying drugs approved for relapsing forms of multiple sclerosis. Their efficacy has been proven in multiple clinical trials. The four therapies licensed as first-line agents (three formulations of interferon-beta and one of glatiramer acetate) have well-established short-term and long-term safety profiles, with manageable adverse events. Results of recent trials suggest that current disease-modifying drugs may have better on-treatment disease suppression than was predicted by the results of the original pivotal studies. Although these therapies are all parenterally administered, a number of technological advances have improved various aspects of injection tolerability and enhanced acceptability, so that the impact of self-injection on the patient's life is minimized. Several promising oral disease-modifying drugs are now in phase III development. However, as these drugs are new to multiple sclerosis therapy, their short-term and long-term safety profiles are unknown. Although novel therapies for multiple sclerosis, particularly orally administered drugs, are eagerly awaited, they will not immediately replace the tried and trusted options.
    Current Opinion in Neurology 02/2009; 22(Suppl 1):S4-S9. DOI:10.1097/01.wco.0000347401.08903.5c · 5.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is an integrative review of Brazilian studies on evidence-based practices (EBP) in health, published in ISI/JCR journals in the last 10 years. The aim was to identify the specialty areas that most accomplished these studies, their foci and methodological approaches. Based on inclusion criteria, 144 studies were selected. The results indicate that most EBP studies addressed childhood and adolescence, infectious diseases, psychiatrics/mental health and surgery. The predominant foci were prevention, treatment/rehabilitation, diagnosis and assessment. The most used methods were systematic review with or without meta-analysis, protocol review or synthesis of available evidence studies, and integrative review. A strong multiprofessional expansion of EBP is found in Brazil, contributing to the search for more selective practices by collecting, recognizing and critically analyzing the produced knowledge. The study also contributes to the analysis itself of ways to do research and new research possibilities.
    Revista da Escola de Enfermagem da U S P 06/2011; 45(3):777-86. DOI:10.1590/S0080-62342011000300033 · 0.45 Impact Factor
Show more

Similar Publications


15 Reads
Available from